Patent application number | Description | Published |
20130052160 | COMPOUNDS AND USES THEREOF TO INDUCE AN IMMUNOGENIC CANCER CELL DEATH IN A SUBJECT - The present invention relates to the fields of genetics, immunology and medicine. The present invention more specifically relates to in vitro or ex vivo methods for determining the susceptibility to a cancer treatment of a subject having a tumour. These methods comprise a step of determining the ability of the treatment, of the subject and/or of the tumour to induce an anticancer immune response, the inability of at least one of the treatment, the subject and the tumor to induce an anticancer immune response being indicative of a resistance of the subject to the therapeutic treatment of cancer. Inventors in particular identify genes specific of a human subject or of cancerous cells which can be used to predict or assess the sensitivity of a subject to a treatment of cancer. The invention also relates to particular compounds capable of activating or enhancing the immune system of a particular subject, when the subject is exposed to a therapeutic treatment of cancer or before such an exposition. It further relates to uses of such compounds, in particular to prepare a pharmaceutical composition to allow or improve the efficiency of a therapy of cancer in a subject in need thereof. The present invention in addition provides kits, methods for selecting a compound of interest, as well as pharmaceutical compositions and uses thereof. | 02-28-2013 |
20130156790 | COMPOUNDS AND USES THEREOF TO INDUCE AN IMMUNOGENIC CANCER CELL DEATH IN A SUBJECT - The present invention relates to the fields of genetics, immunology and medicine. The present invention more specifically relates to in vitro or ex vivo methods for determining the susceptibility to a cancer treatment of a subject having a tumour. These methods comprise a step of determining the ability of the treatment, of the subject and/or of the tumour to induce an anticancer immune response, the inability of at least one of the treatment, the subject and the tumor to induce an anticancer immune response being indicative of a resistance of the subject to the therapeutic treatment of cancer. Inventors in particular identify genes specific of a human subject or of cancerous cells which can be used to predict or assess the sensitivity of a subject to a treatment of cancer. The invention also relates to particular compounds capable of activating or enhancing the immune system of a particular subject, when the subject is exposed to a therapeutic treatment of cancer or before such an exposition. It further relates to uses of such compounds, in particular to prepare a pharmaceutical composition to allow or improve the efficiency of a therapy of cancer in a subject in need thereof. The present invention in addition provides kits, methods for selecting a compound of interest, as well as pharmaceutical compositions and uses thereof. | 06-20-2013 |
20130281313 | PROGNOSTIC AND/OR PREDICTIVE BIOMARKERS AND BIOLOGICAL APPLICATIONS THEREOF - The present invention relates to the fields of genetics, immunology and medicine. The present invention more specifically relates to the identification of human genes and expression products thereof which can be used to assess the prognosis of a cancer in a subject, to assess the sensitivity of a subject to a treatment of cancer, or monitor, in particular determine the efficacy, of such a treatment of cancer after a given period of time. Said human genes and expression products can further be used (i) in the prevention or treatment of cancer, in particular to determine or select the appropriate cancer treatment for a given subject and/or for a particular tumor, as well as (ii) for the screening of therapeutically active drugs. Particular compounds capable to compensate, in a subject, an abnormal expression of one of the herein described products, in particular when the subject is exposed to a therapeutic treatment of cancer, thereby allowing or improving its efficiency in the subject, are also herein disclosed. Inventors, in addition, provide kits and DNA chips usable in the context of the present invention. | 10-24-2013 |
20150185202 | SIMULTANEOUS DETECTION OF CANNIBALISM AND SENESCENCE AS PROGNOSTIC MARKER FOR CANCER - The present inventors show that cannibal cells can undergo senescence after entosis in vivo and that the tumor suppressive protein p53 act as a repressor of this phenomenon. They therefore propose new tools to study the molecular pathways involved in the cannibalism process, for example by measuring the expression levels of p53 or splice variants thereof (such as Δ133TP53, TP53β, TP53γ or Δ40TP53), the release of extracellular ATP or purinergic P2Y2 receptor activity. The present inventors also demonstrated that the detection of senescent cannibal cells in breast adenocarcinoma obtained from patients treated with neo-adjuvant therapy positively correlates with good patient's response to treatment. Altogether, these results provide the first evidence that detection of cellular cannibalism and senescence simultaneously in tumors helps for the diagnosis of disease outcomes and for the prediction of treatment efficiency against cancer diseases. | 07-02-2015 |
Patent application number | Description | Published |
20080299101 | Cancer Treatment Resistance and Agents Modulating Such Resistance - The present invention concerns a method for detecting in vitro resistance of cancer cells to a treatment by detecting in the cancer cells supernumerary nucleolar organizer regions (NOR), whereby identification of the presence of supernumerary NOR in the cancer cells is indicative of treatment resistance. The present invention also concerns a method for defining the capacity of a candidate agent to modulate NOR genes number of cancer cells by contacting the cancer cells with a candidate agent for a time sufficient to permit modulation of NOR genes number; and observing whether NOR genes number increases or decreases in said cancer cells. The present invention also provides a candidate agent that modulates NOR genes number of cancer cells obtained by the method of the invention and a composition for treating and/or preventing a cancer in a patient, comprising said candidate agent. Such a candidate agent decreases the NOR genes number in said cancer cells. | 12-04-2008 |
20100004161 | Toll Like Receptor 4 Dysfunction and the Biological Applications Thereof - The present invention relates to an in vitro method of assessing the sensitivity of a subject to a treatment of cancer, which method comprises detecting the presence of a mutated Toll Like Receptor 4 (TLR4) nucleic acid or an abnormal TLR4 protein expression or activity in a sample from the subject, the presence of said mutated TLR4 nucleic acid or abnormal TLR4 expression or activity being indicative of a resistance to said treatment. The invention further provides compounds for treating or preventing a cancer in a subject having a mutated TLR4 nucleic acid or an abnormal TLR4 protein expression or activity. | 01-07-2010 |
20100015653 | Compounds Regulating Calreticulin, KDEL Receptor and/or ERP-57 Cell Surface Exposure and Uses Thereof to Evaluate the Efficiency of a Cancer Treatment - The present invention relates to a method for determining the susceptibility of a patient tumour cell to a cancer treatment, which method comprises the detection or measure of CRT, KDEL receptor and/or ERp57 on the surface of a tumour cell. | 01-21-2010 |
20100016235 | Inhibitors of Protein Phosphatase 1, GADD34 and Protein Phosphatase 1/GADD34 Complex, Preparation and Uses Thereof - The present invention relates to the use of a protein phosphatase inhibitor selected from an inhibitor of the catalytic subunit of the protein phosphatase 1 (PP1), an inhibitor of GADD34 and an inhibitor of the PP1/GADD34 complex to prepare a pharmaceutical composition to prevent or treat a cancer in a mammal, wherein the pharmaceutical composition is intended for administration in combination with a product used in a treatment of a cancer. | 01-21-2010 |
20100136137 | THERAPEUTIC COMBINATION OF A PANHER/VEGFR2 KINASE INHIBITOR AND A PLATINUM COMPOUND - This invention relates to a synergistic therapeutic combination of anti-cancer compounds which comprises a) a panHER/VEGFR2 kinase inhibitor, and b) a platinum compound, and optionally at least one pharmaceutically acceptable carrier for simultaneous, separate or sequential use. The invention also relates to treating certain cancers utilizing the combination of the invention. | 06-03-2010 |
20110229411 | USE OF P2X7 PATHWAY FOR ASSESSING THE SENSITIVITY OF A SUBJECT TO A CANCER TREATMENT - The present invention concerns methods for assessing the sensibility of a subject to an anticancer treatment, for screening compounds which are useful for treating a cancer and for determining the likelihood of a metastatic relapse in a subject. The methods are based on the finding that a non-functional P2X7-elicited NALP3 inflammasome pathway in a subject is indicative of a resistance to treatment. The invention further concerns methods for treating a cancer and for restoring the sensitivity of the subject to a cancer treatment. | 09-22-2011 |
Patent application number | Description | Published |
20090148496 | IMPLANTS WITH MEMBRANE DIFFUSION-CONTROLLED RELEASE OF ACTIVE INGREDIENT - An implant for implantation in a human or animal body having a structure comprising a) an implant base body; b) a primer layer which is partially or completely applied to the surface of the implant; c) an active ingredient layer consisting of one, two, three or more active ingredients applied entirely or partially to the surface of the primer layer; and d) a diffusion-controlling layer which is applied partially or entirely to the active ingredient layer, and optionally to the primer layer, wherein diffusion of the active ingredients of the active ingredient layer is controlled. Also disclosed is a manufacturing method for an implant. | 06-11-2009 |
20110202486 | Healthcare Information Technology System for Predicting Development of Cardiovascular Conditions - Described herein is a framework for predicting development of a cardiovascular condition of interest in a patient. The framework involves determining, based on prior domain knowledge relating to the cardiovascular condition of interest, a risk score as a function of patient data. The patient data may include both genetic data and non-genetic data. In one implementation, the risk score is used to categorize the patient into at least one of multiple risk categories, the multiple risk categories being associated with different strategies to prevent the onset of the cardiovascular condition. The results generated by the framework may be presented to a physician to facilitate interpretation, risk assessment and/or clinical decision support. | 08-18-2011 |
20150209813 | DEVICE FOR COATING A STENT AND ASSOCIATED COATING METHOD AND STENT PRODUCED ACCORDING TO THE METHOD - The invention relates to a device for coating a stent, comprising a holder for the stent, a spraying unit comprising a spray mandrel and an air nozzle. The spray mandrel, the air nozzle and the holder are designed and disposed relative to each other such that the spray mandrel projects from one side into the stent during coating and the air nozzle projects into the stent from the opposing side. The invention further provides a method for coating a stent which employs the device according to the invention. Finally, the invention relates to stents that can be obtained according to the method. | 07-30-2015 |
Patent application number | Description | Published |
20090071573 | PHOSPHATING SOLUTION WITH HYDROGEN PEROXIDE AND CHELATING CARBOXYLIC ACIDS - The invention relates to a phosphating solution and a process for the phosphating of metallic surfaces with aqueous, acidic phosphating solutions that comprise zinc and phosphate ions, at least one source of peroxide and one or more aliphatic chelating carboxylic acids containing 2 to 7 carbon atoms; the phosphating solution having a free acid content of one point or less. | 03-19-2009 |
20110041957 | OPTIMIZED PASSIVATION ON TI/ZR-BASIS FOR METAL SURFACES - The present invention relates to a chromium-free aqueous agent based on water-soluble compounds of titanium and/or zirconium and a source of fluoride ions, copper ions and metal ions selected from the group consisting of calcium, magnesium, aluminum, boron, zinc, iron, manganese and/or tungstene and to a method for the anti-corrosive conversion treatment of metal surfaces. The chromium-free aqueous agent is suitable for the treatment of various metal materials, joined in composite structures, amongst others of steel or galvanized steel or the alloys thereof or any combinations of said materials. Furthermore, surfaces of aluminum and alloys thereof can be treated in an anti-corrosive manner using the agent according to the invention. The anti-corrosive treatment is intended in particular as a pretreatment for a subsequent dip-coating. The invention further relates to a metallic substrate that was treated according to a predefined method sequence with the chromium-free agent according to the invention and to the use thereof, particularly in the automotive production of vehicle bodies. | 02-24-2011 |
20110062027 | OPTIMIZED ELECTROCOATING OF ASSEMBLED AND PARTLY PREPHOSPHATED COMPONENTS - A process for the anticorrosive treatment of metal components that have been heat-treated at a temperature of at least 100° C. and at least partially comprise zinc surfaces, wherein the surfaces of the component that consist of zinc already partially have a crystalline zinc phosphate layer, wherein the cleaned component is given an activating pretreatment with an acidic aqueous dispersion of insoluble phosphates having a pH of not less than 4 and the component is subsequently subjected to a phosphating conversion treatment before electrocoating is applied. The invention also comprises the use of metal components that have been treated in such a process, for the application of multilayer systems and in particular for the manufacture of bodies in automobile production. | 03-17-2011 |
20110189401 | SUCCESSIVE CORROSION-PROTECTING PRE-TREATMENT OF METAL SURFACES IN A MULTIPLE-STEP PROCESS - The present invention relates to a method for improving the corrosion-protecting pre-treatment of metal surfaces and using rinse water in a manner to conserve resources in such a corrosion-protecting pre-treatment, comprising a conversion treatment step using an aqueous composition comprising at least 50 ppm of the elements B, Si, Ti, Zr and/or Hf in the form of water-soluble compounds at a pH value of 3 to 5.5, wherein a minimum fraction of 10 ppm of the elements B, Si, Ti, Zr and/or Hf in the form of water-soluble compounds is present in the last pre-rinse step and a portion of the aqueous composition of the conversion treatment step is contained in the first post-rinse step. The resource-conserving use of the rinse water is accomplished according to the invention by way of a cascaded return of rinse water from the last rinse step to the first rinse step. The present invention also relates to a metallic component treated using the method according to the invention and to the use thereof in a process for applying a multi-coating system, in particular a paint system containing an organic binder, in industrial manufacturing. | 08-04-2011 |
20120325110 | MULTI-STAGE PRE-TREATMENT METHOD FOR METAL COMPONENTS HAVING ZINC AND IRON SURFACES - The invention relates to an acidic, aqueous, chromium-free composition (A) for the anti-corrosive treatment of steel and/or galvanized steel surfaces comprising metal ions (M) selected from ions at least of the elements nickel, cobalt, molybdenum, iron or tin and a multi-stage method applying the composition (A) for the anti-corrosive pre-treatment of metal components which have steel and/or galvanized steel surfaces. The invention further relates to metal surfaces of zinc or iron having a passive layer system comprising at least 30 mg/m | 12-27-2012 |
20130202800 | COMPOSITION FOR THE ALKALINE PASSIVATION OF ZINC SURFACES - The present invention relates to an aqueous alkaline composition (A) for alkaline passivation of metallic components comprising at least in part surfaces of zinc or zinc alloys, containing iron(III) ions, phosphate ions, and one or more complexing agents, where a free alkalinity ranges from 1 to 6 points, and the pH is at least 11. The aqueous compositions (A) can additionally contain nonionic surfactants, so that such compositions are suitable for use in a method in which both cleaning and alkaline passivation of the metallic component occur in one step. The present invention further relates to a method for alkaline passivation of metallic components by contacting them with composition (A), and further a method for surface treatment in automobile body production, in which the alkaline passivation step using composition (A) is followed by an acid passivation step using a composition (B). | 08-08-2013 |